| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBLN3 |
| Uniprot No | Q12805 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-493aa |
| 氨基酸序列 | MLKALFLTMLTLALVKSQDTEETITYTQCTDGYEWDPVGQQCKDIDECDI VPDACKGGMKCVNHYGGYLCLPKTAQIIVNNEQPQQETQPAEGTSGATTG VVAASSMATSGVLPGGGFVASAAAVAGPEMQTGRNNFVIRRNPADPQRIP SNPSHRIQCAAGYEQSEHNVCQDIDECTAGTHNCRADQVCINLRGSFACQ CPPGYQKRGEQCVDIDECTIPPYCHQRCVNTPGSFYCQCSPGFQLAANNY TCVDINECDASNQCAQQCYNILGSFICQCNQGYELSSDRLNCEDIDECRT SSYLCQYQCVNEPGKFSCMCPQGYQVVRSRTCQDINECETTNECREDEMC WNYHGGFRCYPRNPCQDPYILTPENRCVCPVSNAMCRELPQSIVYKYMSI RSDRSVPSDIFQIQATTIYANTINTFRIKSGSENGEFYLRQTSPVSAMLV LVKSLSGPREHIVDLEMLTASSIGTFRTSSVLRLTIIVGPFSF |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FBLN3(Fibulin-3)重组蛋白的示例参考文献，内容基于领域内常见研究方向整理而成：
---
1. **文献名称**: *"Recombinant Fibulin-3 suppresses angiogenesis through inhibition of VEGF signaling in vitro and in vivo"*
**作者**: Zhang Y, et al.
**摘要**: 该研究报道了重组人FBLN3蛋白通过阻断VEGF受体信号通路抑制内皮细胞迁移和血管生成，提示其在抗肿瘤或视网膜病变中的潜在治疗应用。
2. **文献名称**: *"Expression and characterization of functional recombinant Fibulin-3 in CHO cells for structural analysis"*
**作者**: Lee S, et al.
**摘要**: 作者优化了CHO细胞中重组FBLN3的表达与纯化流程，并通过质谱和圆二色谱验证其正确折叠，为后续功能研究提供高纯度蛋白。
3. **文献名称**: *"Fibulin-3 as a biomarker for early-stage lung cancer: Validation of recombinant protein-based ELISA"*
**作者**: Wang H, et al.
**摘要**: 研究利用重组FBLN3开发新型ELISA检测方法，发现其在肺癌患者血清中显著高表达，提示其作为早期诊断标志物的潜力。
4. **文献名称**: *"Mechanistic insights into Fibulin-3-mediated extracellular matrix remodeling via recombinant protein studies"*
**作者**: Gupta R, et al.
**摘要**: 通过重组FBLN3蛋白的体外实验，揭示了其通过调控MMP-9活性影响细胞外基质重塑的分子机制，可能与组织纤维化疾病相关。
---
**说明**：以上文献为示例性质，实际研究中请通过PubMed、Web of Science等平台检索最新论文。若需具体文献，建议结合关键词(如“recombinant Fibulin-3”、“EFEMP1 expression”)进一步筛选。
**Background of FBLN3 Recombinant Protein**
Fibulin-3 (FBLN3), encoded by the *EFEMP1* gene, is a secreted extracellular matrix (ECM) glycoprotein belonging to the fibulin family, characterized by calcium-binding domains and tandem β-helix structures. It plays critical roles in tissue organization, cell adhesion, and ECM remodeling by interacting with other matrix components like elastin, fibrillin, and integrins. FBLN3 is implicated in both physiological processes (e.g., angiogenesis, elastic fiber assembly) and pathological conditions, including age-related macular degeneration (AMD), tumor progression, and cardiovascular diseases.
Recombinant FBLN3 protein is produced using expression systems (e.g., mammalian or bacterial cells) to ensure proper folding and post-translational modifications, such as glycosylation, which influence its bioactivity. This engineered protein retains functional domains necessary for binding ECM partners and modulating cellular signaling pathways. Studies highlight its dual role in cancer: FBLN3 can suppress primary tumor growth by inhibiting EGFR or PI3K/AKT pathways but may promote metastasis via ECM destabilization. In AMD, FBLN3 mutations or dysregulation contribute to abnormal drusen deposits in the retina, linking it to disease pathogenesis.
As a research tool, recombinant FBLN3 aids in studying ECM dynamics, cell-ECM interactions, and therapeutic targeting. It also holds potential as a biomarker for diseases like glioblastoma or COPD, where its expression correlates with prognosis. Ongoing research aims to clarify its context-dependent functions and therapeutic applications, balancing its dual roles in ECM homeostasis and disease progression.
×
